marketing of proteins and peptide pharmaceuticals
DESCRIPTION
Presented to Ph.D. students of Faculty of Pharmacy of University of Tehran, Nov 2008TRANSCRIPT
Marketing of Peptide, Proteins,
Author: Sasan NasoohiFunction : Sales Manager Schering PloughDate : Nov 08Presented to Ph.D. students of Faculty of Pharmacy of Tehran University
04/12/23 |Peptide, Protein, Economy 2
Proteins, eventually !!
•Our genetic material speaks the tale of proteins
04/12/23 |Peptide, Protein, Economy 3
Proteins: disease and remedy
• Loss in protein production or functionality might lead to serious diseases – Diabetes Mellitus
• Proteins might mediates diseases as well– C-reactive protein mediates cardiovascular disorders.
• Exogenous proteins might mediate serious reactions– Hypersensitivity reactions.
04/12/23 |Peptide, Protein, Economy 4
Proteins are drugs !
Serving or mimicking an endogenous function:Hormonal therapy (Insulin,)
Exploiting an endogenous reaction:Vaccines
Antagonizing an endogenous function:(infliximab)
04/12/23 |Peptide, Protein, Economy 5
From cells to patients
04/12/23 |Peptide, Protein, Economy 6
Peptide Pros and Cons
Advantages:High Activity, High Specifity, Little unspecific binding to molecular structure other that desired target, Minimization of drug-drug interactions, Less accumulation in tissues, Lower toxicity, Often very potent, Biological diversity
DisadvantagesLow oral bioavailability, injection required, Less stable, Difficult delivery and challenge to transport across membranes, Challenging and costly synthesis, Solubility challenges, Risk of immunogenic effects, Cleared from body quickly
04/12/23 |Peptide, Protein, Economy 7
Origin of peptide products
• Synthetic peptides
• Naturally-derived peptides
• Natural, non-blood derived proteins
• Natural, blood derived proteins
• Recombinant proteins
04/12/23 |Peptide, Protein, Economy 8
Peptide Pharmaceuticals
• Annual market value: $ 35 Bln
• Aprox. 40 marketed peptides worldwide
• 270 in clinical phase
• 400 in preclinical phase
• Growth rate double the rate all APIs(Estimated : 10%)
• Expanding interest in peptides for drug discovery
04/12/23 |Peptide, Protein, Economy 9
Protein Therapeutics
• Market size: 60 bln• Growth rate: 13%
• Aprox. 130 marketed protein therapeutics worldwide
04/12/23 |Peptide, Protein, Economy 10
Major Brands > $ 1 Mln
• Procrit (Johnson & Johnson) – epoetin alpha, treatment of anemia
• Epogen (Amgen)- Epoetin , increase of red blood cells
• Rituxan (Genentech)- Rituximab, treatment of rheumatoid arthritis
• Enbrel (Amgen)- Etanercept, treatment of rheumatoid arthritis
• Remicade (Schering Plough) – infliximab, anti-inflammatory
• Herceptin (Chugai)- Trastuzumab – breast cancer treatment
• Humalog ( Eli Lilly)- Insulin - Diabetes
04/12/23 |Peptide, Protein, Economy 11
Major Brands > $ 1 Mln
• Procrit > $2bln $35/ml
• Epogen $37/ml
• Rituxan $70/ml
• Enbrel $160/vial
• Remicade $700/vial
• Herceptin $1200/vial
• Humalog $ 100/vial
04/12/23 |Peptide, Protein, Economy 12
Iran Sales 4 month
• Procrit > $2bln $35/ml
• Epogen $37/ml
• Rituxan $70/ml
• Enbrel $160/vial 1875 vials / 920,000 Rials
• Remicade $700/vial 659 vials / 6,500,000 Rials
• Herceptin $1200/vial 499vials / 8,000,000 Rials
• Humalog $ 100/vial
04/12/23 |Peptide, Protein, Economy 13
Cost-effectiveness
• Follitorpin Urine collection/Recombinant
• Price
• Batch to batch consistency• Novel new product• Less risk of contaminations
04/12/23 |Peptide, Protein, Economy 14
Production Costs
• $300-$500 per g for 300-500 g
• $100-$200 per g for 1-2 Kg
• $25-$ per g for 50-100 Kg
• <$10 per g for high ranges
04/12/23 |Peptide, Protein, Economy 15
What is PharmacoEconomics (PE)?
Inputs
Costs
Health Care
Outcomes
04/12/23 |Peptide, Protein, Economy 16
Pharmacoeconomics (PE)
• Compares the costs and consequences (outcomes) of drug therapies and medical interventions
• PE analysis– efficient allocation of limited resources among competing alternative medications and
services
04/12/23 |Peptide, Protein, Economy 17
Costs
• What is cost?
• How is cost different from price?
• Do we know the cost of drugs?
04/12/23 |Peptide, Protein, Economy 18
Costs
• Direct costs: costs to deliver services to patient; both medical and non-medical
• Indirect costs: cost of treatment to patient or society
• Intangible costs: quality of life
Advantages:High Activity, High Specifity,
Little unspecific binding to molecular structure other that desired target, Minimization of drug-drug interactions, Less accumulation in tissues, Lower toxicity, Often very potent, Biological diversity
04/12/23 |Peptide, Protein, Economy 19
Costs can be described in many ways
• Cost / unit (cost/tab, cost/vial)• Cost / treatment• Cost / person• Cost / person / year• Cost / case prevented• Cost / life saved• Cost / DALY (disability-adjusted life year)
04/12/23 |Peptide, Protein, Economy 20
Outcomes
• Both positive and negative outcomes should be addressed• Positive outcomes: drug’s efficacy measure• Negative outcomes: ADR and treatment failure
04/12/23 |Peptide, Protein, Economy 21
Most Active Developments
• Types: Cytokines , Monoclonal Antibodies, Vaccines
• Segments: Oncology, Cardiovascular, Infection
GPCR
STY kinases
Zinc peptidases
Serine proteases
PDE
Other 110 families
Cys proteases
Gated ion-channel Ion channels
Nuclear receptor
P450 enzymes
04/12/23 |Peptide, Protein, Economy 22
The top 10 biotechnology companies
Ranking Company Country 2007 pharma sales ($m)
% change vs 2006
2007 total revenues ($m)
1 (1) Amgen US 14,311.00 3.3 14,771.00 2 (2) Genentech US 9,443.00 23.6 11,724.00 3 (3) Genzyme US 2,833.28 21.8 3,813.52 4 (4) CSL Australia 2,661.61 24.0 2,779.95 5 (5) Biogen Idec US 2,136.82 20.0 3,171.62 6 (6) Daewoong
Pharmaceutical South Korea 522.98 23.2 522.95
7 (7) Biotest Germany 338.57 31.4 447.44 8 (8) Orchid
Pharmaceuticals India 315.22 47.7 315.23
9 (12) Crucell Netherlands 243.40 86.5 279.34 10 (9) CK Life
Sciences Hong Kong 190.73 6.7 268.10
04/12/23 |Peptide, Protein, Economy 23
Challenges
• 80’s : Technological challenges for peptide delivery
• High R&D and marketing costs
• Large scale manufacturing
• Competitive environment
• Formulation of stable product
• Delivery of the product to body
• Overcoming short bioavailability
• Peptide production still maturing
• Conventional pharmaceutical formulations would destroy most proteins and eliminate their activities:– Pharmaceutical manufacturing includes harsh processing steps that would be harmful for proteins e.g. heating, high shear force, granulation,
compression, etc.
1. Short shelf life of protein preparations:• If kept in correct conditions, must not be used after 4 weeks post opining
04/12/23 |Peptide, Protein, Economy 24
Challenges
Chance of commercialization from Phase I = 10-20%Chance of commercialization from phase III = 60-80%
• 90% of drugs entering clinical trials fail to make it to market
• The average cost to bring a new drug to market is estimated at $770 million
04/12/23 |Peptide, Protein, Economy 25
Current FDA Policy for approval of rDNA-derived Products
• FR Notice (51 FR 23309), June 26, 1986• Points to Consider in the Production Testing of New Drugs and
Biologicals Produced by Recombinant DNA Technology (April 10, 1986)– Protein drug substances produced by rDNA technology cannot be assumed to be
the same.– IND and Full NDA (505(b)(1)) required.
04/12/23 |Peptide, Protein, Economy 26
Determining the Degree of Similarity of Proteins
• Past: Limited ability to characterize the identity, structure, activity of the active components
• Scientific advances: sensitive and validated assays• Accumulated agency’s experience in making determinations of the
similarity and sameness of peptides and proteins• FDA published recommendations on comparability/evaluations in 1996.
04/12/23 |Peptide, Protein, Economy 27
Product Comparability Testing
• Analytical Testing
• Bioassays
• Pre-clinical Animal Studies
• Clinical Studies
04/12/23 |Peptide, Protein, Economy 28
Pharmaceutical Equivalence (PE)
• Identical active drug ingredients• Identical amounts of active ingredients• Identical dosage forms• Identical compendia or other applicable standard of identity, strength, quality,
and purity
04/12/23 |Peptide, Protein, Economy 29
The ICH S6 Document
usage of relevant vs. non-relevant species
usage of animal models of disease immunogenicity testing and its
implicationsgenotoxicity testingchronic toxicity testingcarcinogenicity testingpreclinical study design
04/12/23 |Peptide, Protein, Economy 30
Toxicology Testing of Biotech-Derived Agents: ICH-S6
General Principles sufficiently well-characterized products rely on purification processes to remove
impurities/contaminants comparability of test material demonstrated
throughout development conventional approaches to toxicity studies often
NOT appropriate to address unique issues GLP compliance
04/12/23 |Peptide, Protein, Economy 31
04/12/23 |Peptide, Protein, Economy 32
04/12/23 |Peptide, Protein, Economy 33
04/12/23 |Peptide, Protein, Economy 34
We sell benefits
04/12/23 |Peptide, Protein, Economy 35
Feature of Benefit?
Advantages:High Activity, High Specifity, Little unspecific binding to molecular structure other that desired target, Minimization of drug-drug interactions, Less accumulation in tissues, Lower toxicity, Often very potent, Biological diversity
04/12/23 |Peptide, Protein, Economy 36
• Protein pharmaceuticals